|
Fri, 11/16/2018 - 05:55 |
AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer |
AstraZeneca |
|
Sun, 10/21/2018 - 22:02 |
Roches Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer |
Rocheusa |
|
Wed, 10/17/2018 - 05:43 |
Roche reports very strong growth in the first nine months of 2018 |
Rocheusa |
|
Sun, 08/19/2018 - 22:51 |
China National Drug Administration grants rapid approval of Roches Alecensa (alectinib) as a treatment for ALK-positive lung cancer |
Rocheusa |
|
Wed, 05/16/2018 - 20:22 |
Follow-up phase III data showed Roches Alecensa helped people with ALK-positive metastatic non-small cell lung cancer live a median of almost three years without their disease worsening or death |
Rocheusa |
|
Wed, 05/16/2018 - 15:22 |
Follow-Up Phase III Data Showed Genentechs Alecensa Helped People With Alk-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death |
Genentech |
|
Tue, 05/15/2018 - 23:31 |
Chugais ALK Inhibitor Alecensa Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in Taiwan |
Chugai |
|
Sat, 03/10/2018 - 22:57 |
AstraZeneca provides update on MYSTIC trial timeline |
AstraZeneca |
|
Mon, 02/12/2018 - 07:23 |
U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizers Third-Generation ALK Inhibitor Lorlatinib |
Pfizer |
|
Thu, 02/01/2018 - 00:34 |
Roche reports good results in 2017 |
Rocheusa |
|
Wed, 12/20/2017 - 22:41 |
European Commission approves Roches Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer |
Rocheusa |
|
Wed, 12/20/2017 - 22:29 |
EU Follows US and Approves Chugais ALK Inhibitor "Alecensa " as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer |
Chugai |
|
Sun, 12/03/2017 - 22:44 |
FDA approves Foundation Medicines FoundationOne CDx, the first pan-tumour comprehensive genomic profiling assay incorporating a broad range of companion diagnostics |
Rocheusa |
|
Wed, 11/08/2017 - 04:55 |
Chugai's ALK Inhibitor "Alecensa " Approved for the Treatment of First Line Therapy on ALK-Positive Non-Small Cell Lung Cancer in the US |
Chugai |
|
Mon, 11/06/2017 - 21:30 |
FDA approves Roches Alecensa (alectinib) as first-line treatment for people with specific type of lung cancer |
Rocheusa |
|
Mon, 11/06/2017 - 10:56 |
FDA Approves Genentechs Alecensa (Alectinib) as First-Line Treatment for People with Specific Type of Lung Cancer |
Genentech |
|
Wed, 10/18/2017 - 22:24 |
Roche reports strong sales growth in the first nine months of 2017 |
Rocheusa |
|
Mon, 10/16/2017 - 06:06 |
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer |
Pfizer |
|
Fri, 10/13/2017 - 04:56 |
CHMP recommends EU approval of Roches Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC |
Rocheusa |
|
Mon, 09/11/2017 - 07:56 |
Pfizer Presents Overall Survival Data of XALKORI in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer |
Pfizer |
|
Wed, 09/06/2017 - 01:04 |
Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer |
Rocheusa |
|
Thu, 08/31/2017 - 07:35 |
Roche to present new data from its oncology portfolio at the 2017 European Society for Medical Oncology (ESMO) Congress |
Rocheusa |
|
Wed, 08/02/2017 - 00:42 |
FDA Grants Genentechs Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer |
Genentech |
|
Thu, 07/27/2017 - 01:45 |
AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer |
AstraZeneca |
|
Wed, 07/26/2017 - 22:54 |
Roche reports strong performance in the first half of 2017 |
Rocheusa |
